drugset / Trial / NCT06058988
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
Timeline
- Start
- 2023-09-22
- Primary completion
- 2027-09-22
- Completion
- 2027-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | — | — |